Akero Therapeutics to Announce New Data from NASH Phase 2a BALANCED Study of AKR-001

Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) announced plans to discuss new efficacy and safety data from its Phase 2a BALANCED study of AKR-001 for patients with nonalcoholic steatohepatitis (NASH). The results, including biopsy data, will be shared during a conference call and webcast on June 30, 2020, at 4:30 p.m. ET. Akero aims to address the growing NASH epidemic by developing innovative treatments, with AKR-001 as their lead candidate currently in clinical trials.

Positive

• New efficacy and safety data released for AKR-001 in NASH treatment.
• Conducting a conference call to discuss results indicates transparency.
• Ongoing Phase 2a clinical trial suggests commitment to research and development.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., June 29, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced that the company plans to discuss new efficacy and safety data, including biopsy results, from its Phase 2a BALANCED study of AKR-001 in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) in a post-market press release and webcast to be held on Tuesday, June 30, 2020.

Conference Call / Webcast Details
The company will host a conference call and webcast with slide presentation at 4:30 p.m. ET (1:30 p.m. PT) tomorrow afternoon, June 30. The webcast of the conference call will be made available on the company's website at www.akerotx.com under the Investors tab in the Events, Presentations & Webcasts section. To access the call via dial-in, please dial 1-866-652-5200 (U.S. toll free) or 1-412-317-6060 (international) five minutes prior to the start time. Following the live audio webcast, a replay will be available on the company's website for 90 days.

About Akero Therapeutics
Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance to improve overall health of NASH patients. The company's lead product candidate, AKR-001, is currently being evaluated in an ongoing Phase 2a clinical trial. Akero Therapeutics is headquartered in South San Francisco, CA. For more information, please visit www.akerotx.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/akero-therapeutics-to-announce-new-data-from-nash-phase-2a-balanced-study-of-akr-001-301085264.html

SOURCE Akero Therapeutics, Inc.

FAQ

What are the new findings from Akero's Phase 2a BALANCED study of AKR-001?

Akero is set to present new efficacy and safety data, including biopsy results, from the Phase 2a BALANCED study.

When is the conference call to discuss the new data from the BALANCED study?

The conference call will take place on June 30, 2020, at 4:30 p.m. ET.

What is the significance of the NASH Phase 2a BALANCED study for Akero?

The study results may impact the development and commercial potential of AKR-001 as a treatment for nonalcoholic steatohepatitis.

How can I access the webcast of the conference call about AKR-001?

The webcast will be available on Akero's website under the Investors section.

What is AKR-001 being developed for?

AKR-001 is being developed to treat patients with nonalcoholic steatohepatitis (NASH).